RNS Number:4391N
Celsis International PLC
6 July 2000

                               AGM STATEMENT

The following is an extract from a statement made by Dr. Chris Evans,
Chairman of Celsis, at today's Annual General Meeting.

"In the report and accounts for the year ended 31st March 2000 we reported a
second full year of significant profits increase, with no exceptional costs.
These very positive results establish the Company as a market leader and
leave the Group well placed to exploit many expansion opportunities in its
chosen markets.

"Following the restructuring and reorganisation of the Group in 1998/1999 the
Company is now lead by Sales and Marketing personnel.  A clearly focused
strategy is being pursued, to increase the Company's presence in both new and
existing markets and to capitalise upon our leading products and proprietary
technology.  The Company's research and development activities are also more
closely driven by customer demand and market feedback.

"End Screening continues to provide good revenue growth and offers areas of
significant expansion opportunity for the Company. We will focus on our
Global Corporate Account Management roll out programmes; increasing our
presence in the pharmaceutical industry; and strengthening our leadership
position in existing markets, particularly personal care and dairy products,
through product improvements.

"Celsis Laboratory Group (CLG) is taking advantage of the increasing trend to
outsource testing, from new and current customers.  CLG now provides its
customers with faster quality services at lower costs following the
facilities upgrade.

"The Company will continue to drive forward and direct its own sales in
hygiene monitoring.  Focus on systemSURE and product upgrades in this area
will strengthen our position in hygiene monitoring."


Enquiries

Celsis International plc     Jack Rowell, Chief Executive    +44-1223-426008
Brunswick                    James Garthwaite                +44-207-404-5959


Notes to Editors

Celsis International plc
Celsis International plc specialises in the development and supply of rapid
diagnostic and monitoring systems to detect and measure microbial
contamination.  It has successfully developed tests for use in the food,
beverage, pharmaceutical, cosmetic and toiletries industries.  These tests
are based upon the technology of ATP Bioluminescence; such tests detect the
presence of microbial contamination by monitoring light emitted when
adenosine triphosphate ("ATP"), a naturally occurring substance present in
all living organisms, is brought into contact with luciferase, an enzyme
produced by fireflies.
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Celadon Pharmaceuticals Charts.
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Celadon Pharmaceuticals Charts.